Estramustine phosphate withdrawal syndrome with dramatic pain relief.

Suppr

超能文献

作者信息

Shibata Y, Morita T, Kashiwagi B, Tomizawa H, Yamanaka H

机构信息

Department of Urology, Gunma University School of Medicine, Maebashi, Japan.

出版信息

J Urol. 1999 Sep;162(3 Pt 1):805. doi: 10.1097/00005392-199909010-00056.

DOI:10.1097/00005392-199909010-00056

PMID:10458378

Abstract

摘要

相似文献

Estramustine phosphate withdrawal syndrome with dramatic pain relief.

J Urol. 1999 Sep;162(3 Pt 1):805. doi: 10.1097/00005392-199909010-00056.

Re: Estramustine phosphate withdrawal syndrome with dramatic pain relief.

J Urol. 2000 Apr;163(4):1261.

[Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].

Hinyokika Kiyo. 2008 Jun;54(6):423-6.

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.

Cancer. 2000 Mar 15;88(6):1438-44.

Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.

Int J Urol. 2006 Jul;13(7):1019-21. doi: 10.1111/j.1442-2042.2006.01465.x.

Hemolytic-uremic syndrome during therapy with estramustine phosphate for advanced prostatic cancer.

Oncology. 1999;56(2):112-3. doi: 10.1159/000011950.

[An equivalent of anti-androgen withdrawal syndrome: decrease of prostate specific antigen and clinical response to estramustine phosphate withdrawal].

Presse Med. 1997 Apr 19;26(13):611.

Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.

Onkologie. 2005 Nov;28(11):573-8. doi: 10.1159/000088297.

The use of estramustine phosphate in the modern management of advanced prostate cancer.

BJU Int. 2011 Dec;108(11):1782-6. doi: 10.1111/j.1464-410X.2011.10201.x. Epub 2011 Jul 14.

Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.

Actas Urol Esp. 2014 Apr;38(3):184-91. doi: 10.1016/j.acuro.2013.07.010. Epub 2014 Feb 5.

引用本文的文献

Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.

Mol Oncol. 2014 Dec;8(8):1575-87. doi: 10.1016/j.molonc.2014.06.009. Epub 2014 Jun 24.

Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).

Cancer. 2008 Jun;112(11):2393-400. doi: 10.1002/cncr.23473.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验